These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6840181)

  • 41. Pharmacokinetics of melphalan in children following high-dose intravenous injection.
    Taha IA; Ahmad RA; Rogers DW; Pritchard J; Rogers HJ
    Cancer Chemother Pharmacol; 1983; 10(3):212-6. PubMed ID: 6861266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
    Choi KE; Ratain MJ; Williams SF; Golick JA; Beschorner JC; Fullem LJ; Bitran JD
    Cancer Res; 1989 Mar; 49(5):1318-21. PubMed ID: 2645050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of high-dose melphalan in adults: influence of renal function.
    Kergueris MF; Milpied N; Moreau P; Harousseau JL; Larousse C
    Anticancer Res; 1994; 14(6A):2379-82. PubMed ID: 7825976
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150).
    Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS;
    Biol Blood Marrow Transplant; 2018 May; 24(5):923-929. PubMed ID: 29339269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
    Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Use of intravenous melphalan in the treatment of Kahler's disease].
    Balmes A; Dauverchain J; Othoniel J; Mandin A; Chavanette F
    Presse Med (1893); 1971 May; 7(23):1072. PubMed ID: 5577947
    [No Abstract]   [Full Text] [Related]  

  • 47. Pharmacokinetics of melphalan in isolated perfusion of the limbs.
    Benckhuijsen C; Varossieau FJ; Hart AA; Wieberdink J; Noordhoek J
    J Pharmacol Exp Ther; 1986 May; 237(2):583-8. PubMed ID: 3701643
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Value of intravenous Melphalan in treatment of Kahler's disease].
    Balmes A; Dauverchain J; Mandin A; Othoniel J; Vedel A
    Mars Med; 1969; 106(6):505-8. PubMed ID: 5376451
    [No Abstract]   [Full Text] [Related]  

  • 49. Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.
    Asou N; Izuno Y; Okubo T; Ide K; Ueno H; Kawakita M; Mitsuya H; Hata H
    Int J Hematol; 2007 Jul; 86(1):69-71. PubMed ID: 17675270
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous melphalan and dexamethasone followed by lymphoblastoid alpha interferon in higher risk multiple myeloma patients.
    Petrucci MT; La Verde G; Ribersani M; Avvisati G; Mandelli F
    Leuk Lymphoma; 2000 Sep; 39(1-2):131-8. PubMed ID: 10975391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Melphalan hydrochloride for the treatment of multiple myeloma.
    Esma F; Salvini M; Troia R; Boccadoro M; Larocca A; Pautasso C
    Expert Opin Pharmacother; 2017 Aug; 18(11):1127-1136. PubMed ID: 28658983
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
    Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
    Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
    Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
    Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
    J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repeat administration of high dose melphalan in relapsed myeloma.
    Mansi JL; Cunningham D; Viner C; Ellis E; Meldrum M; Milan S; Gore M
    Br J Cancer; 1993 Nov; 68(5):983-7. PubMed ID: 8217614
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro.
    Ehrsson H; Lewensohn R; Wallin I; Hellström M; Merlini G; Johansson B
    Cancer Chemother Pharmacol; 1993; 31(4):265-8. PubMed ID: 8422688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Maintenance therapy with low-dose of melphalan in multiple myeloma (author's transl)].
    Hirasawa Y; Nagaoka T; Kuto F; Tokuhiro H; Kikawada R
    Rinsho Ketsueki; 1980 Nov; 21(11):1646-54. PubMed ID: 7206225
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.